Histone deacetylation, as opposed to promoter methylation, results in epigenetic BIM silencing and resistance to EGFR TKI in NSCLC

Lignende værker

• Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients
  af: Jiang, Tao, et al.
  Udgivet: (2017)
• Role of BIM Deletion Polymorphism and BIM Expression as Predictive Biomarkers to Maximize the Benefit of EGFR-TKI Treatment in EGFR-Positive NSCLC
  af: Incharoen, Pimpin, et al.
  Udgivet: (2019)
• Vorinostat and metformin sensitize EGFR-TKI resistant NSCLC cells via BIM-dependent apoptosis induction
  af: Chen, Hengyi, et al.
  Udgivet: (2017)
• Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer
  af: Cheng, Ningning, et al.
  Udgivet: (2015)
• First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease
  af: Xu, Qinghua, et al.
  Udgivet: (2019)